Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with P. G.
Contact P. G., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
P071 EQUIP INTERIM RESULTS: A PHASE 1B STUDY EVALUATING ITOLIZUMAB IN SUBJECTS WITH MODERATE-TO-SEVERE UNCONTROLLED ASTHMA
CD6 is a co-stimulatory receptor predominantly expressed on T cells; its ligand, ALCAM, is expressed on antigen presenting, epithelial and endothelial cells. The CD6/ALCAM pathway is elevated in severe asthmatics and is implicated in Th2 and Th1/Th17 driven responses. Itolizumab is a humanized IgG1 monoclonal antibody that binds CD6 and blocks ALCAM interaction to inhibit T cell activation and trafficking.
Abnormal vocal cord movement in patients with and without airway obstruction and asthma symptoms
Abnormal vocal cord movements can cause laryngeal extrathoracic airway obstruction (often called vocal cord dysfunction – VCD) leading to asthma-like symptoms. These aberrant movements are characteristically present during inspiration and termed paradoxical vocal cord movement (PVCM). We have reported PVCM in up to 40% of severe asthmatics, but it is not known if PVCM is detectable in all patients with asthma-like symptoms and if the condition is more often associated with abnormal lung function.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with P. G.
Contact P. G., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack